Robyn L. Woods, PhD, is Associate Professor in the School of Public Health and Preventive Medicine, Monash University, Alfred Hospital campus. She was Director of the aspirin primary prevention clinical trial, ASPREE (ASPirin in Reducing Events in the Elderly), which was conducted in Australia and the United States from 2010 to 2017. It was the largest clinical trial to be conducted in Australia, recruiting 16,703 participants aged 70+ years, across South-Eastern Australia. She continued as Director of the observational follow-on study, ASPREE-XT, until her retirement from that position in 2021. A/Prof Woods continues as an ASPREE investigator, is the ongoing Director of the large ancillary study, the ASPREE Healthy Ageing Biobank, and is currently the Australian PI of the NIH funded ASPREE-Microbiome project (2019-2024). She was co-first author on the New England Journal of Medicine primary paper (2018) describing the main ASPREE results that changed clinical guidelines for preventative aspirin use in older persons. A/Prof Woods has more than 220 research publications.

ASPREE/ASPREE-XT ancillary studies on which A/Prof Woods was/is a CI include the ASPREE Healthy Ageing Biobank (CSIRO; VCA; NCI/NIH), ASPREE-Age-related Macular Degeneration (NEI/NIH; NHMRC), ASPREE-Depression (NHMRC), ASPREE Cancer Endpoints (NCI/NIH; NHMRC), SNORE-ASA (NHMRC), ANTI-SEPSIS (NHMRC) and, currently, Clonal Haematopoiesis of Indeterminate Potential (ASPREE-CHIP-XT) and ASPREE-Microbiome/Biobank/ALSOP project (NIA/NIH). Her special clinical research interests into ageing health and disease include physical disability, frailty, dementia, cardiovascular disease, depression, and declining kidney function in older adults; and the role of aspirin, inflammation and other biomarkers in these key health areas.